RxDoctor Payments Data

Vanessa Hill

Nurse Practitioner · Birmingham, ALNPI 1053634386

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $7,450 of the $11,278 with a category attached, or 66.1%. 10 manufacturers reported payments, led by AbbVie at 46.1% of the total. Reporting peaked in 2021 at $7,206 and has fallen 93.9% since, to $441 in 2025. Among nurse practitioner clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,278in general payments, 2019–2025

Across 65 payments — averaging $173.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Pfizer$2K
  • AstraZeneca$2K
  • Boehringer Ingelheim$825
  • Takeda Pharmaceuticals U.S.A., Inc.$619
  • Johnson & Johnson$237
  • plus $192 from 4 others

What the payments were for

  • Consulting fees$7,45066%
  • Speaking & faculty fees$2,00018%
  • Travel & lodging$3503%
  • Food & beverage$1,42313%
  • Education$550%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,278 in reported general payments places this provider in the 95th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$27,901
Medicare patients
208
Services billed
488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept88$617,476
Humira PenAdalimumab55$422,030
BenlystaBelimumab68$313,411
Humira(Cf) PenAdalimumab41$275,906
Orencia ClickjectAbatacept31$177,751
ActemraTocilizumab33$158,047
Xeljanz XrTofacitinib Citrate24$136,024
Humira(Cf)Adalimumab11$130,023
OtezlaApremilast27$126,996
EnbrelEtanercept14$99,417
OrenciaAbatacept15$90,677
Hydroxychloroquine Sulfate543$44,848
Mycophenolic AcidMycophenolate Sodium17$11,798
MethotrexateMethotrexate Sodium325$9,552
Colchicine119$9,037

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech, Inc.Actemra$16$158,04733 claims
AbbVieHumira(Cf)$5,196$130,02311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →